|
CDC42SE2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.37492272911777E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.78949999263267E-09 |
| Normal-vs-Stage2 |
1.95338999999795E-05 |
| Normal-vs-Stage3 |
4.28868052182452E-12 |
| Normal-vs-Stage4 |
1.01870001323334E-09 |
| Stage1-vs-Stage2 |
5.702000E-01 |
| Stage1-vs-Stage3 |
4.295800E-02 |
| Stage1-vs-Stage4 |
3.749600E-02 |
| Stage2-vs-Stage3 |
5.596200E-01 |
| Stage2-vs-Stage4 |
3.509600E-01 |
| Stage3-vs-Stage4 |
5.533800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.34621219622022E-13 |
| Normal-vs-AfricanAmerican |
2.118300E-03 |
| Normal-vs-Asian |
2.21420000001693E-06 |
| Caucasian-vs-AfricanAmerican |
1.722240E-01 |
| Caucasian-vs-Asian |
7.873400E-01 |
| AfricanAmerican-vs-Asian |
3.574800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.0573999948148E-08 |
| Normal-vs-Female |
5.6120663671777E-12 |
| Male-vs-Female |
6.242600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.30070000051263E-07 |
| Normal-vs-Age(41-60Yrs) |
2.55509946534005E-10 |
| Normal-vs-Age(61-80Yrs) |
3.933298131642E-11 |
| Normal-vs-Age(81-100Yrs) |
5.962600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.193170E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.641300E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.789400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.055220E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.477000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.772800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.296400E-03 |
| Classical-VS-Follicular |
5.578800E-01 |
| Classical-VS-Other |
2.552400E-01 |
| Classical-VS-Normal |
2.89499979544416E-10 |
| Tall-VS-Follicular |
9.759900E-02 |
| Tall-VS-Other |
9.521200E-01 |
| Tall-VS-Normal |
1.5008000397998E-09 |
| Follicular-VS-Other |
4.610400E-01 |
| Follicular-VS-Normal |
5.28099999952403E-07 |
| Other-VS-Normal |
1.916650E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.49330001089731E-09 |
| Normal-vs-N1 |
1.58799973171142E-10 |
| N0-vs-N1 |
6.612300E-02 |
|
|
